Physician profile
Gervasio Lamas
NPI 1396779088
$1,486.93
in general payments reported to CMS, 2019-2025
20 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.10 · 2020: $71.38 · 2021: $265 · 2022: $133 · 2023: $38.45 · 2024: $442 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $274.00 | 2020-2021 | |
| Atricure, INC. | $229.28 | 2022-2024 | |
| Boston Scientific Corporation | $184.07 | 2025 | Watchman Flx |
| Novo Nordisk INC | $143.26 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Heartflow, INC. | $110.36 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $105.37 | 2024-2025 | Camzyos, Eliquis |
| Angiodynamics, INC. | $65.07 | 2019-2021 | |
| Glaxosmithkline, LLC. | $58.08 | 2024-2025 | Shingrix, Arexvy |
| Madrigal Pharmaceuticals | $47.73 | 2024 | Resmetirom |
| Pfizer INC. | $43.60 | 2024-2025 | |
| Baxter Healthcare | $42.19 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Edwards Lifesciences Corporation | $30.50 | 2024 | |
| Medicomp INC | $30.00 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $25.45 | 2023 | Inpefa |
| Amgen INC. | $24.61 | 2024 | Repatha |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21.95 | 2025 | Farxiga |
| Abbott Laboratories | $21.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.76 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gervasio Lamas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.